UTILE is currently analysing all previously granted Health projects in FP7 and H2020 to select commercially promising project results for further commercial exploitation.
For this goal we have designed a selection methodology consisting of two evaluation rounds. In the first round projects are assessed by the four different TTO (Technology Transfer Office) partners. For this purpose the TTO partners have designed an assessment tool. Assessment is based on publicly available project data from CORDIS (the European Commission’s primary public repository to disseminate information on all EU-funded research projects and their results).
Shortly after the summer we investigated the first 597 projects that had been through the first round assessment to try and describe what kind of projects these were. When the highest assessed projects (scoring a 1 or 2 on a 5 point scale) were broken down the following technology types emerged (the figure in parentheses indicating the number of funded projects):
- Diagnostics (63)
- Therapeutics (small molecule) (44)
- Research tools (84)
- Novel drug targets (28)
These high scoring projects can be segmented into the following therapeutic areas:
- Cancer (32)
- Infection (31)
- Inflammatory and immune system (17)
- Metabolic and endocrine (17)
- Neurological (incl. stroke) (17)
A little over a half (54%) of these high scoring projects were at TRL 5, 6 or 7 at the time of their final summary report, another quarter at TRL 3 and 4. Maybe surprisingly the single largest group (19%) were at TRL 2.
Out of the 597 projects, 55% were assessed as having no potential in the project for valorisation. This could be due to the nature of the involved research (policy studies etc.) or because the results of the project were assessed as being outdated, insufficient etc.
The high scoring projects will continue to the second round of assessment in Deep Dive to better understand the assets they may have produced.
Please stay tuned for future updates!
